Clinical Trial for Mesothelioma Patients: Antineoplaston Therapy Concurrent Therapy Criteria
Read the concurrent therapy criteria for a current clinical trial being conducted to study the effects of Antineoplaston therapy for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Prior Concurrent Therapy:
Biologic therapy:
• At least 4 weeks since prior immunotherapy and recovered
• No concurrent immunomodulatory agents
Chemotherapy:
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
Endocrine therapy:
• Concurrent corticosteroids allowed
Radiotherapy:
• At least 8 weeks since prior radiotherapy (or less if multiple tumors) and recovered
Surgery:
• Recovered from prior surgery
Other:
• Prior cytodifferentiating agents allowed
• No prior antineoplastons
• No other concurrent antineoplastic agents
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney



Clinical trial to study effects of Bortezomib on mesothelioma patients